Skip to Main Content

Paper Details

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Neurology: Neuroimmunology and NeuroInflammation
10
2021
MS, Multiple Sclerosis, NFL, NTZ, Natalizumab, PML, Patients, Serum NFL, Serum Neurofilament, multiple sclerosis, natalizumab, neurofilament light chain, patients, progressive multifocal leukoencephalopathy, relapsing-remitting MS, serum NFL
Author NameAffiliation
Ayman TourbahInstitut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., CPTP INSERM UMR 3 CNRS UMR 5282 et Universite de Toulouse III, Spain University Lille (P.V.), Inserm U1172, France Universite (A.R.), Bordeaux CHU de Bordeaux (A.R.), INSERM-CHU CIC-P 0005, INSERM U1215 Department of Neurology (J.dS), CHU de Reims, URCA LPN EA2027 Universite Paris VIII (A.T.), CNRS, CHU de Nice Pasteur2, Universite Nice Cote d'Azur UR2CA URRIS
Jean PelletierInstitut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., CPTP INSERM UMR 3 CNRS UMR 5282 et Universite de Toulouse III, Spain University Lille (P.V.), Inserm U1172, France Universite (A.R.), Bordeaux CHU de Bordeaux (A.R.), INSERM-CHU CIC-P 0005, INSERM U1215 Department of Neurology (J.dS), CHU de Reims, URCA LPN EA2027 Universite Paris VIII (A.T.), CNRS, CHU de Nice Pasteur2, Universite Nice Cote d'Azur UR2CA URRIS
Xavier MontalbanInstitut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., CPTP INSERM UMR 3 CNRS UMR 5282 et Universite de Toulouse III, Spain University Lille (P.V.), Inserm U1172, France Universite (A.R.), Bordeaux CHU de Bordeaux (A.R.), INSERM-CHU CIC-P 0005, INSERM U1215 Department of Neurology (J.dS), CHU de Reims, URCA LPN EA2027 Universite Paris VIII (A.T.), CNRS, CHU de Nice Pasteur2, Universite Nice Cote d'Azur UR2CA URRIS
David BrassatInstitut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., CPTP INSERM UMR 3 CNRS UMR 5282 et Universite de Toulouse III, Spain University Lille (P.V.), Inserm U1172, France Universite (A.R.), Bordeaux CHU de Bordeaux (A.R.), INSERM-CHU CIC-P 0005, INSERM U1215 Department of Neurology (J.dS), CHU de Reims, URCA LPN EA2027 Universite Paris VIII (A.T.), CNRS, CHU de Nice Pasteur2, Universite Nice Cote d'Azur UR2CA URRIS
Manuel ComabellaInstitut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain CRC-SEP Neurosciences Centre Hospitalier Universitaire Toulouse (B.P., CPTP INSERM UMR 3 CNRS UMR 5282 et Universite de Toulouse III, Spain University Lille (P.V.), Inserm U1172, France Universite (A.R.), Bordeaux CHU de Bordeaux (A.R.), INSERM-CHU CIC-P 0005, INSERM U1215 Department of Neurology (J.dS), CHU de Reims, URCA LPN EA2027 Universite Paris VIII (A.T.), CNRS, CHU de Nice Pasteur2, Universite Nice Cote d'Azur UR2CA URRIS
  • 1 - 5

Datasets

Release 1.2